Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors (rIL-2(LAK))
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The present protocol is a phase 2 study designed to investigate the potential application of allogeneic cell-mediated immunotherapy in metastatic solid tumors, similarly to the well established graft versus leukemia (GVL) effects, in patients with metastatic solid tumors resistant to conventional treatment modalities. Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2 (LAK) followed by rIL-2 inoculation in vivo. This treatment is aiming to induce an anti-tumor effect mediated by the efficient killing activity of the rIL-2 activated cells. Prior to cell infusion patients will receive the conditioning treatment with low dose Cyclophosphamide (Cyc) or Fludarabine with 2 injections of low dose alpha interferon. Cell therapy will be combined with specific anti-tumor monoclonal antibodies if available for the specific disease. Further activation of the anti-tumor activity of alloreactive donor T cells and natural killer (NK) cells will be accomplished by in vivo inoculation of rIL-2, aiming for enhancing the anti-cancer potential of donor-derived effectors cells. Patients will receive one - three cycles of cell therapy, as long as there are no signs of Graft- versus - Host - disease (GVHD) and the malignant disease is controlled.
| Condition | Intervention | Phase |
|---|---|---|
|
Metastatic Breast Cancer Malignant Melanoma Renal Cell Cancer Gastrointestinal Cancer |
Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | rIL-2 Activated Allogeneic Lymphocytes for the Induction of Graft Versus Tumor Effect (GVT) in Metastatic Solid Tumors |
- CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion. [ Time Frame: on day +7 day +17, day +28 post cell therapy. ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2009 |
| Estimated Study Completion Date: | January 2011 |
| Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
-
Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically
Eligibility| Ages Eligible for Study: | 12 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Consenting patients (age 12-70) will be eligible for participation in the study involving anti-tumor immunotherapy provided the following criteria are met:
Evidence of cancer not expected to be cured with conventional modalities:
Pediatric patients: Chemotherapy-resistant neuroblastoma stage 4 & sarcomas. Adult patients: Metastatic breast cancer, malignant melanoma, renal cell cancer and selected cases of ovary cancer, gastrointestinal cancer, small-cell and non-small cell lung cancer with non-bulky metastatic disease, metastatic prostate cancer.
- Patients with measurable disease evaluable for response with anticipated life expectancy >3 months.
- Patients must be >2 weeks off anti-cancer or potentially immunosuppressive treatment.
- Adequate ambulatory performance status (Karnofsky >80%; ECOG 0-1) to enable outpatient treatment (see Appendix 1).
- Compliant and cooperative patients anticipated to be evaluable for response according to investigator's assessment.
- HLA-noncompatible (partial matched or mismatched) donor available.
Exclusion Criteria:
Patients will be excluded from participation in the study if any of the following criteria are met:
- Any of the above criteria are not met.
- Patients with a significant history or current evidence of potentially severe cardiovascular disease.
- Hepatic and/or renal failure.
- Abnormal PT and PTT.
- Patients with abnormal hemogram (PMN<1.0x109/L; HB<10; Plts<50x109/L)
- Evidence of serious active infection requiring antibiotic therapy.
- Evidence of active disease requiring steroid or cytotoxic therapy.
- Pregnancy.
- Contraindication for donation due to donor disease: HIV-1; HBsAg positivity.
Contacts and Locations| Contact: Preuven Or, Prof., M.D. | 972-(2)-6776561 | reuvenor@hadassah.org.il |
| Contact: Liliane Dray, RN | 972-(50)-8573250 | Lilane@hadassah.org.il |
| Israel | |
| Hadassah University Hospital | Recruiting |
| Jerusalem, Israel, 91120 | |
| Contact: Reuven Or, Prof., M.D. 972-(2)-6776551 reuvenor@hadassah.org.il | |
| Contact: Liliane Dray, RN 972-(50)-8573250 Lilane@hadassah.org.il | |
| Principal Investigator: Reuven Or, Prof., M.D. | |
| Sub-Investigator: Igor B. Resnick, Prof., M.D.,Ph.D., D. Sci | |
| Sub-Investigator: Michael Y Shapira, M.D. | |
| Sub-Investigator: Bejumin Gesundheit, M.D. | |
| Principal Investigator: | Reuven Or, Prof., M.D. | Hadassah University Hospital |
More Information
No publications provided
| Responsible Party: | Prof. Reuven Or, Hadassah Medical Organization |
| ClinicalTrials.gov Identifier: | NCT00855452 History of Changes |
| Other Study ID Numbers: | 0457-08-HMO-CTIL |
| Study First Received: | February 19, 2009 |
| Last Updated: | March 3, 2009 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by Hadassah Medical Organization:
|
GVL rIL-2(LAK) GVHD |
MST alloCT alloBMT |
Additional relevant MeSH terms:
|
Breast Neoplasms Carcinoma, Renal Cell Melanoma Gastrointestinal Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Kidney Neoplasms |
Urologic Neoplasms Urogenital Neoplasms Kidney Diseases Urologic Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nevi and Melanomas Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases |
ClinicalTrials.gov processed this record on May 16, 2013